Equine viral vaccines: the past, present and future

被引:74
作者
Minke, JM
Audonnet, JC
Fischer, L
机构
[1] Merial SAS, Dept Project Management, F-69007 Lyon, France
[2] Merial SAS, Dept Mol Biol, F-69007 Lyon, France
[3] Merial SAS, Dept Gene Therapy, F-69007 Lyon, France
关键词
horse; viral diseases; vaccinology; novel strategies;
D O I
10.1051/vetres:2004019
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The increasing international movement of horses combined with the relaxation of veterinary regulations has resulted in an increased incidence of equine infectious diseases. Vaccination, along with management measures, has become the primary method for the effective control of these diseases. Traditionally modified live and inactivated vaccines have been used and these vaccines have proven to be very successful in preventing disease. However, there are a number of equine infectious diseases for which conventional technology has shown its limitations. The advent of recombinant technology has stimulated the development of second generation vaccines, including gene deleted Mutants, live vectored vaccines and DNA vaccines. These vaccines have in common that protective antigens are endogenously processed and presented along the molecules of the MHC I and MHC II complex, resulting in the stimulation of both humoral and cell-mediated immune responses similar to natural infection. The present paper provides a review of the vaccines being employed today against the most important equine viral diseases followed by a summary of new developments that are expected to bring improved vaccines to the market in the foreseeable future.
引用
收藏
页码:425 / 443
页数:19
相关论文
共 102 条
[1]  
Allen G P, 1986, Prog Vet Microbiol Immunol, V2, P78
[2]  
ALLEN GP, 1985, AM J VET RES, V46, P138
[3]  
ALLEN GP, 1998, EQUINE INFECT DIS, V8, P129
[4]  
[Anonymous], VACCINE
[5]  
AUDONNET JC, 1998, EQUINE INFECT DIS, V8, P418
[6]   Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses [J].
Balasuriya, UBR ;
Heidner, HW ;
Davis, NL ;
Wagner, HM ;
Hullinger, PJ ;
Hedges, JF ;
Williams, JC ;
Johnston, RE ;
Wilson, WD ;
Liu, IK ;
MacLachlan, NJ .
VACCINE, 2002, 20 (11-12) :1609-1617
[7]   Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus [J].
Bennett, AM ;
Lescott, T ;
Phillpotts, RJ .
VIRAL IMMUNOLOGY, 1998, 11 (03) :109-117
[8]   ATTENUATION OF VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS BY IN VITRO CULTIVATION IN GUINEA-PIG HEART CELLS [J].
BERGE, TO ;
TIGERTT, WD ;
BANKS, IS .
AMERICAN JOURNAL OF HYGIENE, 1961, 73 (02) :209-&
[9]  
BOWEN RA, 1992, VACCINE RES, V1, P111
[10]  
BRYANS JT, 1966, J AM VET MED ASSOC, V148, P413